[Commentary: External validity of studies on Primary Care prevention of Hypercholesterolemia].
作者信息
Brotons C
机构信息
EAP Sardenya. Servei Català de la Salut. Barcelona. España.
出版信息
Aten Primaria. 2003 Nov 30;32(9):514-6. doi: 10.1016/s0212-6567(03)70780-x.
Abstract
摘要
相似文献
1
[Commentary: External validity of studies on Primary Care prevention of Hypercholesterolemia].
Aten Primaria. 2003 Nov 30;32(9):514-6. doi: 10.1016/s0212-6567(03)70780-x.
2
[Validity in a community (with outside verification) of primary prevention studies on hypercholesterolemia].
Aten Primaria. 2003 Nov 30;32(9):509-13. doi: 10.1016/s0212-6567(03)70779-3.
3
[Primary prevention in hypercholesterolemia. High HDL cholesterol levels and female gender underestimated protective factors].
Lakartidningen. 2006;103(3):131-4.
4
[Primary and secondary prevention of coronary disease by statins].
Ann Cardiol Angeiol (Paris). 1999 Feb;48(2):128-36.
5
A need to redefine the consensus on the use of statins in coronary heart disease prevention.
Eur Heart J. 2000 Oct;21(19):1572-3. doi: 10.1053/euhj.2000.2387.
6
Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program.
Arch Intern Med. 1999;159(15):1670-8. doi: 10.1001/archinte.159.15.1670.
7
Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugs.
Lancet. 2002 Jun 29;359(9325):2271-3. doi: 10.1016/S0140-6736(02)09299-1.
8
Primary and secondary prevention of coronary heart disease. Evidence offers multiple strategies.
Adv Nurse Pract. 2000 Jun;8(6):36-41; quiz 42-3.
9
National cholesterol education program (NCEP) guidelines too complex.
Prev Cardiol. 2005 Summer;8(3):188. doi: 10.1111/j.1520-037x.2005.4358.x.
10
Toward better therapy of hypercholesterolemia.
Arch Intern Med. 2000 Sep 25;160(17):2685-6. doi: 10.1001/archinte.160.17.2685.
本文引用的文献
1
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
Lancet. 2003 Apr 5;361(9364):1149-58. doi: 10.1016/S0140-6736(03)12948-0.
2
On the waves of the Seven Countries Study: a public health perspective on cholesterol.
Eur Heart J. 1999 Jun;20(11):796-802. doi: 10.1053/euhj.1998.1357.
3
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
JAMA. 1998 May 27;279(20):1615-22. doi: 10.1001/jama.279.20.1615.
4
[Practical clinical implications of megastudies for primary prevention].
Rev Esp Cardiol. 1997 May;50(5):295-9.
5
Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
Circulation. 1994 Oct;90(4):1679-87. doi: 10.1161/01.cir.90.4.1679.
6
Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.
Circulation. 1995 Oct 1;92(7):1758-64. doi: 10.1161/01.cir.92.7.1758.
7
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
N Engl J Med. 1995 Nov 16;333(20):1301-7. doi: 10.1056/NEJM199511163332001.
Zotero 插件